Copyright Reports & Markets. All rights reserved.

Global Liposomal and Lipid-based Nanoparticle Drug Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Liposomes Drugs
    • 1.2.3 Lipid Nanoparticle Drugs
  • 1.3 Market by Application
    • 1.3.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospital
    • 1.3.3 Retail Pharmacy
    • 1.3.4 Other
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Perspective (2016-2027)
  • 2.2 Liposomal and Lipid-based Nanoparticle Drug Growth Trends by Regions
    • 2.2.1 Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Liposomal and Lipid-based Nanoparticle Drug Historic Market Share by Regions (2016-2021)
    • 2.2.3 Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Regions (2022-2027)
  • 2.3 Liposomal and Lipid-based Nanoparticle Drug Industry Dynamic
    • 2.3.1 Liposomal and Lipid-based Nanoparticle Drug Market Trends
    • 2.3.2 Liposomal and Lipid-based Nanoparticle Drug Market Drivers
    • 2.3.3 Liposomal and Lipid-based Nanoparticle Drug Market Challenges
    • 2.3.4 Liposomal and Lipid-based Nanoparticle Drug Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue
    • 3.1.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue (2016-2021)
    • 3.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2016-2021)
  • 3.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Liposomal and Lipid-based Nanoparticle Drug Revenue
  • 3.4 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio
    • 3.4.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Liposomal and Lipid-based Nanoparticle Drug Revenue in 2020
  • 3.5 Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Area Served
  • 3.6 Key Players Liposomal and Lipid-based Nanoparticle Drug Product Solution and Service
  • 3.7 Date of Enter into Liposomal and Lipid-based Nanoparticle Drug Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Type

  • 4.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Type (2016-2021)
  • 4.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2022-2027)

5 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Application

  • 5.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Application (2016-2021)
  • 5.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
  • 6.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
    • 6.2.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
    • 6.2.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
    • 6.2.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
  • 6.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
    • 6.3.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
    • 6.3.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
    • 6.3.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
  • 6.4 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
    • 6.4.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
    • 6.4.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
  • 7.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
    • 7.2.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
    • 7.2.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
    • 7.2.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
  • 7.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
    • 7.3.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
    • 7.3.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
    • 7.3.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
  • 7.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
    • 7.4.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
    • 7.4.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
  • 8.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
    • 8.2.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
    • 8.3.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region
    • 8.4.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
  • 9.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
    • 9.2.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
    • 9.2.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
    • 9.2.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
  • 9.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
    • 9.3.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
    • 9.3.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
    • 9.3.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
  • 9.4 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
    • 9.4.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
    • 9.4.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size (2016-2027)
  • 10.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
    • 10.2.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
    • 10.3.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country
    • 10.4.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Johnson & Johnson
    • 11.1.1 Johnson & Johnson Company Details
    • 11.1.2 Johnson & Johnson Business Overview
    • 11.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.1.4 Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.1.5 Johnson & Johnson Recent Development
  • 11.2 Sun Pharmaceutical
    • 11.2.1 Sun Pharmaceutical Company Details
    • 11.2.2 Sun Pharmaceutical Business Overview
    • 11.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.2.4 Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.2.5 Sun Pharmaceutical Recent Development
  • 11.3 CSPC
    • 11.3.1 CSPC Company Details
    • 11.3.2 CSPC Business Overview
    • 11.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.3.4 CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.3.5 CSPC Recent Development
  • 11.4 Kinyond
    • 11.4.1 Kinyond Company Details
    • 11.4.2 Kinyond Business Overview
    • 11.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.4.4 Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.4.5 Kinyond Recent Development
  • 11.5 Teva
    • 11.5.1 Teva Company Details
    • 11.5.2 Teva Business Overview
    • 11.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.5.4 Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.5.5 Teva Recent Development
  • 11.6 Fudan-Zhangjiang
    • 11.6.1 Fudan-Zhangjiang Company Details
    • 11.6.2 Fudan-Zhangjiang Business Overview
    • 11.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.6.4 Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.6.5 Fudan-Zhangjiang Recent Development
  • 11.7 Zydus Cadila
    • 11.7.1 Zydus Cadila Company Details
    • 11.7.2 Zydus Cadila Business Overview
    • 11.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.7.4 Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.7.5 Zydus Cadila Recent Development
  • 11.8 TTY Biopharma
    • 11.8.1 TTY Biopharma Company Details
    • 11.8.2 TTY Biopharma Business Overview
    • 11.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.8.4 TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.8.5 TTY Biopharma Recent Development
  • 11.9 Pacira
    • 11.9.1 Pacira Company Details
    • 11.9.2 Pacira Business Overview
    • 11.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.9.4 Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.9.5 Pacira Recent Development
  • 11.10 Luye Pharma
    • 11.10.1 Luye Pharma Company Details
    • 11.10.2 Luye Pharma Business Overview
    • 11.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.10.4 Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.10.5 Luye Pharma Recent Development
  • 11.11 Leadiant Biosciences
    • 11.11.1 Leadiant Biosciences Company Details
    • 11.11.2 Leadiant Biosciences Business Overview
    • 11.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.11.4 Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.11.5 Leadiant Biosciences Recent Development
  • 11.12 Ipsen
    • 11.12.1 Ipsen Company Details
    • 11.12.2 Ipsen Business Overview
    • 11.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.12.4 Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.12.5 Ipsen Recent Development
  • 11.13 Sayre Therapeutics
    • 11.13.1 Sayre Therapeutics Company Details
    • 11.13.2 Sayre Therapeutics Business Overview
    • 11.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.13.4 Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.13.5 Sayre Therapeutics Recent Development
  • 11.14 Jazz
    • 11.14.1 Jazz Company Details
    • 11.14.2 Jazz Business Overview
    • 11.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.14.4 Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.14.5 Jazz Recent Development
  • 11.15 Alnylam
    • 11.15.1 Alnylam Company Details
    • 11.15.2 Alnylam Business Overview
    • 11.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.15.4 Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.15.5 Alnylam Recent Development
  • 11.16 Bausch Health
    • 11.16.1 Bausch Health Company Details
    • 11.16.2 Bausch Health Business Overview
    • 11.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.16.4 Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.16.5 Bausch Health Recent Development
  • 11.17 Acrotech Biopharma
    • 11.17.1 Acrotech Biopharma Company Details
    • 11.17.2 Acrotech Biopharma Business Overview
    • 11.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.17.4 Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.17.5 Acrotech Biopharma Recent Development
  • 11.18 Takeda
    • 11.18.1 Takeda Company Details
    • 11.18.2 Takeda Business Overview
    • 11.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Introduction
    • 11.18.4 Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
    • 11.18.5 Takeda Recent Development
  • 11.18 Chiesi Farmaceutici

.1 Chiesi Farmaceutici Company Details

    .2 Chiesi Farmaceutici Business Overview

      .3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Introduction

        .4 Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)

          .5 Chiesi Farmaceutici Recent Development

          • 11.20 Gilead Sciences
            • 11.20.1 Gilead Sciences Company Details
            • 11.20.2 Gilead Sciences Business Overview
            • 11.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Introduction
            • 11.20.4 Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2016-2021)
            • 11.20.5 Gilead Sciences Recent Development

          12 Analyst's Viewpoints/Conclusions

            13 Appendix

            • 13.1 Research Methodology
              • 13.1.1 Methodology/Research Approach
              • 13.1.2 Data Source
            • 13.2 Disclaimer

            Global Liposomal and Lipid-based Nanoparticle Drug Scope and Market Size
            Liposomal and Lipid-based Nanoparticle Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Liposomal and Lipid-based Nanoparticle Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

            Segment by Type
            Liposomes Drugs
            Lipid Nanoparticle Drugs

            Segment by Application
            Hospital
            Retail Pharmacy
            Other

            By Region
            North America
            United States
            Canada
            Europe
            Germany
            France
            U.K.
            Italy
            Russia
            Nordic
            Rest of Europe
            Asia-Pacific
            China
            Japan
            South Korea
            Southeast Asia
            India
            Australia
            Rest of Asia
            Latin America
            Mexico
            Brazil
            Rest of Latin America
            Middle East & Africa
            Turkey
            Saudi Arabia
            UAE
            Rest of MEA

            By Company
            Johnson & Johnson
            Sun Pharmaceutical
            CSPC
            Kinyond
            Teva
            Fudan-Zhangjiang
            Zydus Cadila
            TTY Biopharma
            Pacira
            Luye Pharma
            Leadiant Biosciences
            Ipsen
            Sayre Therapeutics
            Jazz
            Alnylam
            Bausch Health
            Acrotech Biopharma
            Takeda
            Chiesi Farmaceutici
            Gilead Sciences

            Buy now